Rankings
▼
Calendar
RYTM (Rhythm Pharmaceuticals, Inc.) Stock Financials & Earnings | Market Cap Arena
RYTM
Rhythm Pharmaceuticals, Inc.
Mkt Cap
$6B
Healthcare
·
Biotechnology
·
🇺🇸 United States
·
NASDAQ
Revenue (TTM)
$190M
Net Income (TTM)
-$197M
EPS (TTM)
-$3.11
Free Cash Flow (TTM)
-$117M
Gross Margin
89.7%
Op. Margin
-101.2%
Net Margin
-103.6%
FCF Margin
-61.5%
P/S Ratio (TTM)
33.6x
P/E Ratio (TTM)
—
YoY Rev Growth
+45.8%
Employees
—
Earnings Reports
▶
Q4 2025
NEW
Browse All Reports
Quarterly
FY
Revenue & Profitability
Revenue
Gross Profit
Operating Income
Quarter
Revenue
Gross Profit
Op. Income
Q1 23
$11M
$10M
-$53M
Q2 23
$19M
$17M
-$47M
Q3 23
$23M
$20M
-$44M
Q4 23
$24M
$21M
-$41M
Q1 24
$26M
$23M
-$140M
Q2 24
$29M
$26M
-$40M
Q3 24
$33M
$29M
-$44M
Q4 24
$42M
$38M
-$41M
Q1 25
$33M
$29M
-$47M
Q2 25
$49M
$43M
-$45M
Q3 25
$51M
$46M
-$53M
Q4 25
$57M
$52M
-$47M
marketcaparena.com
Valuation
P/S Ratio
P/E Ratio
Quarter
P/S
P/E
Q1 23
189.7x
—
Q2 23
145.7x
—
Q3 23
102.9x
—
Q4 23
82.4x
—
Q1 24
69.4x
—
Q2 24
62.6x
—
Q3 24
56.7x
—
Q4 24
49.0x
—
Q1 25
46.6x
—
Q2 25
40.8x
—
Q3 25
36.6x
—
Q4 25
33.6x
—
marketcaparena.com
Operating Cash Flow
Operating Cash Flow
Free Cash Flow
Quarter
Operating CF
Free CF
Q1 23
-$36M
-$36M
Q2 23
-$41M
-$42M
Q3 23
-$29M
-$29M
Q4 23
-$29M
-$29M
Q1 24
-$41M
-$81M
Q2 24
-$29M
-$29M
Q3 24
-$25M
-$25M
Q4 24
-$19M
-$19M
Q1 25
-$40M
-$40M
Q2 25
-$23M
-$23M
Q3 25
-$27M
-$27M
Q4 25
-$25M
-$26M
marketcaparena.com
Capital Expenditures
CapEx
Quarter
CapEx
Q1 23
$47K
Q2 23
$875K
Q3 23
$1K
Q4 23
$1K
Q1 24
$40M
Q2 24
$0
Q3 24
$0
Q4 24
$0
Q1 25
$0
Q2 25
$0
Q3 25
$0
Q4 25
$953K
marketcaparena.com
OpEx vs Revenue Growth (YoY)
Revenue Growth
OpEx Growth
Quarter
Revenue Growth
OpEx Growth
Q1 23
+665.6%
+18.1%
Q2 23
+112.0%
+21.5%
Q3 23
+425.3%
+52.6%
Q4 23
+175.7%
+28.7%
Q1 24
+126.4%
+159.1%
Q2 24
+51.3%
+5.7%
Q3 24
+47.8%
+16.1%
Q4 24
+72.6%
+26.8%
Q1 25
+25.9%
-51.9%
Q2 25
+66.8%
+34.9%
Q3 25
+54.3%
+34.8%
Q4 25
+36.9%
+25.6%
marketcaparena.com
Stock-Based Compensation
SBC ($)
% of Revenue
Quarter
SBC ($)
% of Revenue
Q1 23
$6M
55.6%
Q2 23
$9M
46.3%
Q3 23
$9M
38.3%
Q4 23
$9M
35.8%
Q1 24
$8M
29.9%
Q2 24
$10M
35.6%
Q3 24
$11M
33.1%
Q4 24
$11M
25.2%
Q1 25
$13M
39.3%
Q2 25
$16M
32.7%
Q3 25
$19M
36.7%
Q4 25
$19M
33.7%
marketcaparena.com
OpEx Breakdown
R&D
SG&A
Quarter
R&D
SG&A
Q1 23
$38M
$25M
Q2 23
$34M
$30M
Q3 23
$34M
$30M
Q4 23
$30M
$32M
Q1 24
$128M
$34M
Q2 24
$30M
$36M
Q3 24
$38M
$35M
Q4 24
$41M
$38M
Q1 25
$37M
$39M
Q2 25
$42M
$46M
Q3 25
$46M
$52M
Q4 25
$42M
$57M
marketcaparena.com
Revenue Segments
Product revenue
Product
Quarter
Product revenue
Product
Q2 23
$19M
—
Q3 23
$23M
—
Q1 24
—
$26M
Q2 24
—
$29M
Q2 25
—
$49M
Q3 25
—
$51M
marketcaparena.com
Revenue by Geography
Germany
Other Countries
United States
Quarter
Germany
Other Countries
United States
Q3 24
$4M
$6M
$23M
marketcaparena.com
War Chest
Cash & Equivalents
Short-Term Investments
Quarter
Cash
Short-term Investments
Total
Q1 23
$110M
$185M
$295M
Q2 23
$116M
$138M
$254M
Q3 23
$65M
$235M
$299M
Q4 23
$60M
$216M
$276M
Q1 24
$53M
$148M
$201M
Q2 24
$162M
$157M
$319M
Q3 24
$48M
$251M
$298M
Q4 24
$89M
$231M
$321M
Q1 25
$106M
$208M
$314M
Q2 25
$136M
$155M
$291M
Q3 25
$52M
$364M
$416M
Q4 25
$54M
$335M
$389M
marketcaparena.com
Shares Outstanding
Shares Outstanding
Quarter
Shares (Diluted)
QoQ Change
Q1 23
57M
+0.7%
Q2 23
57M
+0.3%
Q3 23
58M
+1.8%
Q4 23
59M
+2.3%
Q1 24
60M
+1.6%
Q2 24
61M
+1.4%
Q3 24
61M
+0.3%
Q4 24
62M
+0.6%
Q1 25
63M
+2.4%
Q2 25
64M
+1.0%
Q3 25
64M
+1.0%
Q4 25
67M
+3.9%
marketcaparena.com
Revenue Per Employee
Revenue / Employee
Year
Revenue/Employee
Employees
FY 14
—
—
FY 15
—
—
FY 16
—
—
FY 17
$0
26
FY 18
$0
54
FY 19
$0
70
FY 20
$0
90
FY 21
$23K
140
FY 22
$134K
177
FY 23
$343K
226
FY 24
$460K
283
FY 25
$474
400K
marketcaparena.com